GLP-1 RA have demonstrated a sustained weight reduction in CVOTs and are recommended in patients with T2DM and obesity.15 It is therefore not surprising that in our analysis a BMI ≥30 kg/m2 was associated with higher likelihood of use. This evidence concerns the gene GLP1R and obesity disorder.